잠시만 기다려 주세요. 로딩중입니다.

Bone Health Issues in Patients with Prostate Cancer: An Evidence-Based Review

The World Journal of Men′s Health 2020년 38권 2호 p.151 ~ 163
Walz Simon, Maas Moritz, Stenzl Arnulf, Todenhofer Tilman,
소속 상세정보
 ( Walz Simon ) - Eberhard Karls University Department of Urology
 ( Maas Moritz ) - Eberhard Karls University Department of Urology
 ( Stenzl Arnulf ) - Eberhard Karls University Department of Urology
 ( Todenhofer Tilman ) - Eberhard Karls University Department of Urology

Abstract


Bone health in prostate cancer patients represents a prerequisite for acceptable quality of life and optimal outcome of this disease. The major threat for bone health in prostate cancer displays cancer treatment induced bone loss as well as the development of bone metastases. In recent years, several new pharmaceuticals targeting bone metabolism such as denosumab or androgen pathway targeting drugs (abiraterone acetate and enzalutamide) have been approved for the treatment of progressive disease aiming to interrupt the vicious circle of bone metastasis and aberrant bone resorption. This development raised the awareness of the pivotal role of bone health in prostate cancer and introduced (symptomatic) skeletal related events as an important end point in recent clinical trials. Bone targeted drugs have become standard of care in patients with metastatic castration resistant prostate cancer, their role in metastatic hormone sensitive prostate cancer has been discussed controversely. In oligometastatic prostate cancer patients several promising approaches in metastasis directed therapy, including conventional surgery, stereotactic ablative radiation and image-guided single-fraction robotic stereotactic radiosurgery (CyberKnife®) were launched but are not in routine clinical use until now caused by sparse clinical evidence.

키워드

Bone; Bone loss; Bone-targeted therapy; Cancer treatment induced bone loss; Metastasis; Prostatic neoplasms

원문 및 링크아웃 정보

 

등재저널 정보

SCI(E)
KCI
KoreaMed